SCHEMBL2007979

SCHEMBL2007979

COc1ccc2c(c1)cc(C)n2S(=O)(=O)c1cccc(NCCN(C)C)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 3/20 0.42
HTR6 P50406 11/20 0.42
RAD52 P43351 1/20 0.41
NQO1 P15559 1/20 0.40
ACLY P53396 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LCK P06239 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
HTR1A P08908 1/20 0.36
DRD2 P14416 1/20 0.36
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36
HTR1E P28566 1/20 0.36
HTR1F P30939 1/20 0.36
HTR7 P34969 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2312698 0.76 HTR6 (0.50) NQO2HTR6RAD52NQO1HTR1A
SCHEMBL3555665 0.67 HTR6 (0.63) HTR6ACLYHTR1ADRD2HTR1D
SCHEMBL2008376 0.67 HTR6 (0.54) NQO2HTR6HTR1ADRD2HTR1D
SCHEMBL2005448 0.65 HTR6 (0.53) HTR6HTR1ADRD2HTR1DHTR1B
SCHEMBL2008614 0.64 HTR6 (0.55) NQO2HTR6NQO1HTR1ADRD2
SCHEMBL2006196 0.64 HTR6 (0.57) NQO2HTR6HTR1ADRD2HTR1D
SCHEMBL2009721 0.63 HTR6 (0.53) HTR6HTR1ADRD2HTR1DHTR1B
SCHEMBL2008525 0.63 HTR6 (0.57) HTR6HTR1ADRD2HTR1DHTR1B
SCHEMBL2013274 0.63 FABP4 (0.48) HTR6RAD52
SCHEMBL2006044 0.62 HTR6 (0.55) NQO2HTR6HTR1ADRD2HTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200980-B9 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION SUVEN LIFE SCIENCES LTD (IN) 2011-12-28 EP claimed
EP-2200980-B1 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION SUVEN LIFE SCIENCES LTD (IN) 2011-08-03 EP claimed
US-7964627-B2 Amino arylsulfonamide compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2011-06-21 US claimed
US-20100216861-A1 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-08-26 US claimed
US-7964627-B2 Amino arylsulfonamide compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100216861-A1 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216861-A1 AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS HTR6, HTR5A, HTR1A NQO2 1862/4885HTR6 1/4885RAD52 4523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.